Swiss Lions rankings | 2026 edition
Basilea
Basilea is No. 13 in the Pharma & Biotech ranking, with a score of 19.3 out of 100. It is not among the Swiss Lions 100 for 2026. Headquarters: Allschwil, canton of Basel-Landschaft.
- Swiss Lions score
- 19.3
- Swiss Lions 100
- Not in the 100 for 2026
- Pharma & Biotech
- 13of 15
About
Allschwil-based commercial-stage biopharmaceutical company, listed on SIX Swiss Exchange, that develops and sells medicines for severe bacterial and fungal infections, notably the antifungal Cresemba.
Basilea Pharmaceutica is a commercial-stage biopharmaceutical company focused on anti-infectives for severe bacterial and fungal infections. Founded in 2000 and listed on SIX Swiss Exchange, it has launched two hospital brands: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera. Its products are commercialised mainly through licensing and distribution partners, including Pfizer, in the United States, Europe, Japan, China and other markets, and Cresemba was marketed in more than 70 countries by the end of 2024. Royalty income, mainly from Cresemba, was CHF 111.6 million in 2025. Its pipeline includes the antifungal fosmanogepix in Phase 3 and the oral antibiotic ceftibuten-ledaborbactam. Total revenue was CHF 232.4 million in 2025.
- Cresemba (isavuconazole) antifungal
- Zevtera antibiotic
- Fosmanogepix (Phase 3 antifungal)
- Ceftibuten-ledaborbactam (oral antibiotic)
Links
How the score is made
Global scale
CHF 232m revenue.
Swiss value
Limited Swiss production.
Global visibility
Online attention across languages, and worldwide search interest.
Impact
No current SBTi target. Not a certified B Corp.
Philanthropy
No charitable foundation found.
Impact and philanthropy together make up the impact measure. How the ranking works.
Key figures
- Revenue used in the ranking
- CHF 232m2025, company
Shares and listing
- Stock exchange
- SIX Swiss ExchangeTicker BSLN
- ISIN
- CH0011432447
- Market value
- CHF 851 millionAt the close on 23 October 2026. Source: stockanalysis.com.
- Free float
- 92.5%Shares not held by large long-term shareholders. Source: in.marketscreener.com.
Profit, dividends and employee numbers are published in the company's annual report.
We have not found a published figure for employees in Switzerland for 2025 or 2026, and dividends paid to Swiss shareholders are not published, so neither is shown.
Profile
- Headquarters
- AllschwilCanton of Basel-Landschaft
- Language region
- German-speaking
- Category
- Pharma & Biotech
- Ownership
- Listed, no controlling shareholder
- Chief executive
- David VeitchSince 2018. Source
- Chair
- Stephan SchindlerSource
- Global reach
- Cresemba marketed in more than 70 countriesSource
- Founded
- 2000
In Switzerland
- Allschwil BLHeadquarters
Over time
| Year | Revenue |
|---|---|
| 2025 | CHF 232m |
| 2024 | CHF 209m |
| 2023 | CHF 158m |
| 2022 | CHF 148m |
As reported by the company, in its reporting currency. Group figures where the brand is part of a group only if stated.
Milestones
- 2000Basilea Pharmaceutica founded in Basel.
- 2018David Veitch succeeds Ronald Scott as chief executive on 19 April.
- 2024Cresemba marketed in more than 70 countries by year-end.
- 2025Revenue rises 11.4% to CHF 232.4 million.
Also in Pharma & Biotech
1RocheScore 77.2
2NovartisScore 75.5
3LonzaScore 56.3
4SandozScore 52.1
5FerringScore 49.8
6SiegfriedScore 44.1
See all 15 brands in Pharma & Biotech.
Sources
- Revenue used in the ranking: biospace.com (2025).
- Company profile, sites, history and milestones: biospace.com, basilea.com, finanzen.ch.
- Climate target: Science Based Targets initiative dashboard, October 2026. Foundations: Swiss commercial register. B Corp: B Lab directory.
Something out of date?
If a figure is wrong, or Basilea can publish figures for the next edition, tell us. Corrections are recorded with their source.